Cargando…
Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945039/ https://www.ncbi.nlm.nih.gov/pubmed/20637100 http://dx.doi.org/10.1186/ar3087 |
_version_ | 1782187166739202048 |
---|---|
author | Gilson, Mélanie Gossec, Laure Mariette, Xavier Gherissi, Dalenda Guyot, Marie-Hélène Berthelot, Jean-Marie Wendling, Daniel Michelet, Christian Dellamonica, Pierre Tubach, Florence Dougados, Maxime Salmon, Dominique |
author_facet | Gilson, Mélanie Gossec, Laure Mariette, Xavier Gherissi, Dalenda Guyot, Marie-Hélène Berthelot, Jean-Marie Wendling, Daniel Michelet, Christian Dellamonica, Pierre Tubach, Florence Dougados, Maxime Salmon, Dominique |
author_sort | Gilson, Mélanie |
collection | PubMed |
description | INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA infections during TNFα-blocker treatments. Each case was compared to two controls (with TJA and TNFα-blocker therapy, but without TJA infection) matched on age (±15 years), TJA localization, type of rheumatic disorder and disease duration (±15 years). Statistical analyses included univariate and multivariate analyses with conditional logistic regression. RESULTS: In the 20 cases (18 rheumatoid arthritis), TJA infection concerned principally the knee (n = 12, 60%) and the hip (n = 5, 25%). Staphylococcus was the more frequent microorganism involved (n = 15, 75%). Four patients (20%) were hospitalized in an intensive care unit and two died from infection. Eight cases (40%) versus 5 controls (13%) had undergone primary TJA or TJA revision for the joint subsequently infected during the last year (P = 0.03). Of these procedures, 5 cases versus 1 control were performed without withdrawing TNFα-blockers (P = 0.08). In multivariate analysis, predictors of infection were primary TJA or TJA revision for the joint subsequently infected within the last year (odds ratio, OR = 88.3; 95%CI 1.1-7,071.6; P = 0.04) and increased daily steroid intake (OR = 5.0 per 5 mg/d increase; 1.1-21.6; P = 0.03). Case-control comparisons showed similar distribution between TNFα-blockers (P = 0.70). CONCLUSIONS: In patients receiving TNFα-blockers, TJA infection is rare but potentially severe. Important risk factors are primary TJA or TJA revision within the last year, particularly when TNFα-blockers are not interrupted before surgery, and the daily steroid intake. |
format | Text |
id | pubmed-2945039 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29450392010-09-25 Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study Gilson, Mélanie Gossec, Laure Mariette, Xavier Gherissi, Dalenda Guyot, Marie-Hélène Berthelot, Jean-Marie Wendling, Daniel Michelet, Christian Dellamonica, Pierre Tubach, Florence Dougados, Maxime Salmon, Dominique Arthritis Res Ther Research Article INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA infections during TNFα-blocker treatments. Each case was compared to two controls (with TJA and TNFα-blocker therapy, but without TJA infection) matched on age (±15 years), TJA localization, type of rheumatic disorder and disease duration (±15 years). Statistical analyses included univariate and multivariate analyses with conditional logistic regression. RESULTS: In the 20 cases (18 rheumatoid arthritis), TJA infection concerned principally the knee (n = 12, 60%) and the hip (n = 5, 25%). Staphylococcus was the more frequent microorganism involved (n = 15, 75%). Four patients (20%) were hospitalized in an intensive care unit and two died from infection. Eight cases (40%) versus 5 controls (13%) had undergone primary TJA or TJA revision for the joint subsequently infected during the last year (P = 0.03). Of these procedures, 5 cases versus 1 control were performed without withdrawing TNFα-blockers (P = 0.08). In multivariate analysis, predictors of infection were primary TJA or TJA revision for the joint subsequently infected within the last year (odds ratio, OR = 88.3; 95%CI 1.1-7,071.6; P = 0.04) and increased daily steroid intake (OR = 5.0 per 5 mg/d increase; 1.1-21.6; P = 0.03). Case-control comparisons showed similar distribution between TNFα-blockers (P = 0.70). CONCLUSIONS: In patients receiving TNFα-blockers, TJA infection is rare but potentially severe. Important risk factors are primary TJA or TJA revision within the last year, particularly when TNFα-blockers are not interrupted before surgery, and the daily steroid intake. BioMed Central 2010 2010-07-16 /pmc/articles/PMC2945039/ /pubmed/20637100 http://dx.doi.org/10.1186/ar3087 Text en Copyright ©2010 Gilson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Gilson, Mélanie Gossec, Laure Mariette, Xavier Gherissi, Dalenda Guyot, Marie-Hélène Berthelot, Jean-Marie Wendling, Daniel Michelet, Christian Dellamonica, Pierre Tubach, Florence Dougados, Maxime Salmon, Dominique Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title_full | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title_fullStr | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title_full_unstemmed | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title_short | Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
title_sort | risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945039/ https://www.ncbi.nlm.nih.gov/pubmed/20637100 http://dx.doi.org/10.1186/ar3087 |
work_keys_str_mv | AT gilsonmelanie riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT gosseclaure riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT mariettexavier riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT gherissidalenda riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT guyotmariehelene riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT berthelotjeanmarie riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT wendlingdaniel riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT micheletchristian riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT dellamonicapierre riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT tubachflorence riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT dougadosmaxime riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy AT salmondominique riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy |